Krazati (adagrasib tablets - Mirati Therapeutics) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has unresectable and metastatic disease
• Patient has KRAS G12C mutation-positive disease
• Patient has been previously treated with at least one systemic regimen

Approval duration

1 year